Actively Recruiting
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Led by iOMEDICO AG · Updated on 2026-01-28
2950
Participants Needed
1
Research Sites
531 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with hematological malignancies in Germany.
CONDITIONS
Official Title
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Confirmed diagnosis of the respective non-Hodgkin lymphoma
- Signed written informed consent if patient is alive
- For patients in the patient-reported outcomes survey: consent before or on the start day of the treatment line
- For patients not in the patient-reported outcomes survey: consent within eight weeks after starting the treatment line
You will not qualify if you...
- No systemic therapy received for the respective lymphoid malignancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Praxis für Interdisziplinäre Hämatologie und Onkologie
Freiburg im Breisgau, Germany
Actively Recruiting
Research Team
M
Martina Jänicke, Dr.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here